Eric Halioua – President & CEO, PDC*line Pharma
PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last…
Address: Namur Office Park
Avenue des dessus de Lives, 6
5101 NAMUR-LOYERS,Belgium
Tel: +32(0)81/33.28.50
Web: http://www.investinwallonia.be/?lang=en
Wallonia’s economy is very focused on the global market and it is one of the largest exporters per capital worldwide.
To support the establishment of prospective foreign investors, the Wallonia government set up a specially trained team in the late 1990s with the objective of assisting all foreign investors in the implementation of their investment project in Wallonia.
This team is called the Office for Foreign Investors (O.F.I) and it forms part of the Agence Wallonne à l’Exportation et aux Investissements étrangers (Wallonia agency for exports and foreign investment).
With the support of public and private players, O.F.I. assists at all stages in successfully establishing businesses in Wallonia by providing invaluable advice in the following spheres: choice of location, grant schemes, tax regime, recruitment and training of staff, project financing arrangements.
Grant schemes, Tax regime, Recruitment and Training of staff, Project financing
PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last…
Once primarily associated with dispensing medications alone, many pharmacies have now evolved into dynamic healthcare hubs, offering a diverse range of services that extend far beyond traditional prescription filling. Similarly,…
The concepts of patient-centricity and patient-centred healthcare systems have been much discussed in recent years but, in the opinion of Stefan Gijssels, there is still a long road to travel…
Pierre Boyer, GM at Servier BeLux for the past six years, outlines the unique characteristics and challenges of the Belgian market and shares the company’s 2030 strategy, its unique approach…
Gedeon Richter Benelux’s Isabelle de Walsche gives an update on the affiliate’s progress towards becoming a reference player in women’s health, looks back on some of her achievements over 11…
Luc Van Gorp is president of the Christian Mutuality, Belgium’s largest health insurance fund. In a wide-ranging recent conversation with PharmaBoardroom, Van Gorp expanded on some of the key themes…
Xavier De Cuyper of the Federal Agency for Medicines & Health Products (FAMHP), Belgium’s drug regulator, explains the FAMHP’s pandemic response and lessons learned, how the Agency is keeping on…
As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to…
Gábor Sztaniszláv talks through the global relevance of Belux to Amgen’s operations, some of the challenging market access conditions at play – especially for orphan drugs -, and how the…
Marc Gryseels of BACHI, Belgium’s over-the-counter (OTC) medicines association, highlights the organisation’s mission and vision, the key trends at play within the Belgian consumer healthcare market, and his industry’s significant…
Despite the thriving life sciences ecosystem that has made Belgium one of the top European destinations for clinical trials, the country continues to grapple with considerable access challenges and remains…
pharma.be is the association of the Belgian R&D-based pharmaceutical industry, representing over 42,000 employees at 130 companies. CEO Caroline Ven outlines the crucial role that pharma.be and its members played…
See our Cookie Privacy Policy Here